Gitnux/Report 2026

Healthcare and Pharmaceutical Industry Statistics

The United States accounted for 53% of global prescription pharmaceutical sales in 2025, explore the figures behind growth, companies and trends across healthcare and pharmaceutical.
61Statistics
34Sources
10Sections
1Visuals
21mRead
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 32 days

01 Industry overview

The healthcare and pharmaceutical industry at a glance

U.S. national health spending was projected at $5.7 trillion in 2025, while global prescription pharmaceutical sales reached an estimated $1.7 trillion, reflecting strong demand and continued innovation.

$5.7T[3]
U.S. health spending, 2025
5.4%[3]
U.S. health spending CAGR, 2025–34
355,400[9]
Pharma manufacturing jobs, 2025
46[12]
FDA novel drugs approved, 2025
Market size
U.S. national health spending was projected to reach $5.7 trillion in 2025, equal to 18.4% of GDP. Global prescription pharmaceutical list-price sales were estimated at $1.674 trillion in 2025.[3][16]
Forecast & CAGR
CMS projects U.S. national health expenditures to grow at an average annual rate of 5.4% from 2025 through 2034, reaching approximately $9.0 trillion by 2034. Health spending is projected to rise from 18.0% of GDP in 2024 to 20.6% in 2034.[3]
Market share & regions
The United States accounted for 53% of global prescription pharmaceutical sales by value in 2025, compared with 24% for Europe and 11% for Japan. The figures indicate a highly U.S.-centered global market despite broad international demand.[16]
Segmentation
U.S. 2025 projected health spending included $1.74 trillion from private health insurance, $1.20 trillion from Medicare, $1.03 trillion from Medicaid and CHIP, and $577 billion in out-of-pocket spending. Hospital expenditures alone reached $1,634.7 billion in 2024.[17][3]
Key players & concentration
The global pharmaceutical market is concentrated geographically: the United States represented 53% of prescription sales in 2025, while Europe and Japan together represented 35%. Company-level concentration was not reported in a sufficiently comparable primary source.[16]
Pricing
For 47 drugs approved in 2025, the median annual U.S. net launch price was estimated at $257,369 and the median list price was $293,304. Nearly one-quarter of these drugs launched at annual net prices above $500,000.[18][19]
Trends, drivers & challenges
Growth is being driven by higher utilization, hospital and physician-service demand, GLP-1 medicines and cancer treatments; CMS projected U.S. health spending growth of 7.3% in 2025. Key challenges include affordability, high launch prices, workforce needs and slower projected growth of 6.3% in 2026.[3][20]
Consumer behavior & competition
The United States spent $14,885 per person on health in 2024, the highest level among OECD countries and more than twice the OECD average. Competition is increasing through generic medicines: FDA approved 689 abbreviated new drug applications in fiscal 2025.[21][12]
M&A
Johnson & Johnson completed its acquisition of clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in December 2025. The transaction added a targeted oncology platform and illustrates continued large-pharma demand for late-stage and platform biotechnology assets.[22]
Regulation
FDA’s Center for Drug Evaluation and Research approved 46 novel drugs in calendar 2025; 39, or 85%, were approved on the first review cycle. CMS also projects that federal government-sponsored programs will account for 33% of national health expenditure by 2034, up from 31% in 2024.[12][3]
Latest news
The latest major official industry outlook is CMS’s 2025–2034 projection, which estimates that U.S. national health spending reached $5.7 trillion in 2025 and will reach approximately $9.0 trillion by 2034. The projection highlights strong near-term utilization growth followed by slower growth after 2026.[3][20]

02 Ranking

Top 10 Companies in the Healthcare And Pharmaceutical Industry

The leading companies in the healthcare and pharmaceutical industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 21, 2026 · Next review December 21, 2026

Verdict

Eli Lilly and Company stands out for innovative medicines and biologics because its 2025 revenue reached $65.2 billion with Mounjaro and Zepbound, while Roche is the pick for pharmaceuticals and diagnostics since it reported CHF61.5 billion in 2025 sales.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in innovative medicines and biologics

    Eli Lilly and Company

    US

    Ranked #1 · 9.3 · Innovative medicines and biologics

    Why we picked it: Its innovative medicines and biologics portfolio centers on Mounjaro and Zepbound, with $65.2 billion revenue in 2025.

  2. Leader in pharmaceuticals and diagnostics

    Roche

    CH

    Ranked #2 · 9.0 · Pharmaceuticals and diagnostics

    Why we picked it: Its pharmaceuticals-and-diagnostics mix is reflected in CHF61.5 billion sales in 2025 and a 19.8% R&D intensity.

  3. Leader in prescription medicines

    Novartis

    CH

    Ranked #3 · 8.9 · Prescription medicines

    Why we picked it: Its innovative prescription medicines business spans development, manufacturing and sales in about 120 countries.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the healthcare and pharmaceutical industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Innovative medicines and biologics · US

9.3
2

Roche

Pharmaceuticals and diagnostics · CH

9.0
3

Novartis

Prescription medicines · CH

8.9
4

Novo Nordisk

Diabetes and obesity medicines · DK

8.9
5

AstraZeneca

Patient-impact biopharmaceuticals · GB

8.9
6

Merck

Prescription medicines, vaccines and animal health · US

8.3
7

Sanofi

Vaccines and specialty medicines · FR

8.3
8

Pfizer

Biopharmaceuticals and vaccines · US

8.2
9

Amgen

Biotechnology and specialty medicines · US

8.2
10

Elevance Health

Health insurance and integrated health services · US

8.1

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 21, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 21). Top 10 companies in the healthcare and pharmaceutical industry. In Healthcare And Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/healthcare-and-pharmaceutical-industry-statistics/#top-companies

report visual · Comparison

Health expenditure as a share of GDP, OECD average

Health expenditure as a share of GDP, OECD average: 8.8% in 2019, 9.3% in 2024.

20209.6%
20219.6%
20249.3%
20229.1%
20239.1%
20198.8%
source-verifiedoecd.org2024

04 Statistics

Technology & AI

Hospitals are integrating predictive AI into electronic health records at scale, with 71% of U.S. non-federal acute-care hospitals reporting this in 2024.

AI and automation in the healthcare and pharmaceutical industry

  • 71% of U.S. non-federal acute-care hospitals reported predictive AI integrated with their electronic health record in 2024, up from 66% in 2023.[1]
  • 86% of U.S. system-affiliated hospitals used predictive AI in 2024, compared with 37% of independent hospitals.[1]
  • 90% of U.S. hospitals using the market-leading EHR vendor reported predictive-AI use in 2024, versus 50% using other vendors.[1]

Tools, systems and equipment in the healthcare and pharmaceutical industry

  • Nearly all U.S. office-based physicians used electronic health records in 2024, according to the National Electronic Health Record Survey of 1,725 physicians.[1]
  • 86% of U.S. hospitals affiliated with a health system used predictive AI in 2024, showing concentration of delivery tooling among system-affiliated providers.[1]
  • 98.97% of U.S. health centers reported certified electronic health technology installed at all service-delivery sites and used by all providers in 2024.[2]

05 Statistics

Market Intelligence

Spending detail shows where demand concentrates, including $467.0 billion spent on prescription drugs in the United States in 2024.

Market size and service revenue in the healthcare and pharmaceutical industry

  • $1.6347 trillion was spent on hospital care in the United States in 2024, within CMS national health expenditure accounts.[3]
  • $5.3 trillion was spent on U.S. healthcare in 2024, covering national health expenditures for healthcare goods, services, public health activities, administration, insurance and investment.[3]
  • $1.1097 trillion was spent on physician and clinical services in the United States in 2024, within CMS national health expenditure accounts.[3]
  • $467.0 billion was spent on prescription drugs in the United States in 2024, within CMS national health expenditure accounts.[3]

Growth forecasts for the healthcare and pharmaceutical industry

  • U.S. hospital-care spending is projected to grow at an average annual rate of 5.2% from 2025 through 2034.[3]
  • U.S. national health expenditures are projected to grow at an average annual rate of 5.4% from 2025 through 2034.[3]
  • U.S. retail prescription-drug spending is projected to grow at an average annual rate of 5.7% from 2025 through 2034.[3]
  • U.S. national health expenditures are projected to reach $9.0 trillion in 2034, compared with $5.3 trillion in 2024, in CMS projections.[3]

Firm counts and size structure in the healthcare and pharmaceutical industry

  • 7,164,388 employees worked at U.S. healthcare and social-assistance establishments with 500 or more employees in 2022.[4]
  • 4,360 U.S. healthcare and social-assistance establishments had 500 or more employees in the 2022 Economic Census.[4]
  • $518.4 billion was the annual payroll of U.S. healthcare and social-assistance establishments with 500 or more employees in 2022.[4]

Demand shifts in the healthcare and pharmaceutical industry

  • Medicaid enrollment fell 8.6% from 92.2 million in 2023 to 84.3 million in 2024 in the United States.[3]
  • Private health-insurance enrollment rose 3.5% from 207.0 million in 2023 to 214.3 million in 2024 in the United States.[3]
  • Marketplace enrollment rose from 16.2 million in 2023 to 21.1 million in 2024 in the United States.[3]

06 Statistics

Strategy & Growth

Transaction activity is rising in biotechnology and pharmaceutical deals, with 392 healthcare, pharmaceutical, information and technology transactions recorded globally in 2025.

M&A and consolidation in the healthcare and pharmaceutical industry

  • Biotechnology and pharmaceutical companies accounted for 35% of all global healthcare transactions in 2025.[5]
  • 392 healthcare, pharmaceutical, information and technology transactions were recorded globally in 2025, up from 353 in 2024.[6]
  • 1,455 biotechnology and pharmaceutical transactions occurred globally in 2025, compared with 1,540 in 2024.[5]
  • $31 billion was the aggregate value of global healthcare, pharmaceutical, information and technology transactions in 2025, up 72% from $18 billion in 2024.[6]

07 Statistics

Clients & Demand

Coverage remains high while enrollment shifts continue, including 21.1 million people on the U.S. health-insurance Marketplace in 2024.

Service penetration and outsourcing in the healthcare and pharmaceutical industry

  • 91.8% of the U.S. population had health-insurance coverage in 2024, the insured share reported by CMS.[3]
  • 214.3 million people were enrolled in private health insurance in the United States in 2024.[3]
  • 21.1 million people were enrolled in the U.S. health-insurance Marketplace in 2024.[3]

08 Statistics

Delivery & Operations

Standing capacity is reflected in more than 22,000 NHSC-approved sites available across the United States on September 30, 2024.

Delivery capacity and installed base in the healthcare and pharmaceutical industry

  • More than 16,200 service-delivery sites were operating in the U.S. Health Center Program in 2025, indicating standing primary-care capacity.[2]
  • 1,109,460 physicians were practicing in the United States in 2023, a qualified-practitioner capacity measure for healthcare delivery.[7]
  • 17,419 primary medical, oral-health and behavioral-health practitioners served NHSC-approved sites in the United States on September 30, 2024.[8]
  • More than 22,000 NHSC-approved sites were available across the United States on September 30, 2024.[8]

09 Statistics

People & Workforce

Workforce demand is supported by continued job growth, with healthcare and social assistance adding 686,000 jobs in the United States during 2025.

Employment and hiring in the healthcare and pharmaceutical industry

  • Healthcare and social assistance added 686,000 jobs in the United States during 2025, including 387,000 healthcare jobs and 299,000 social-assistance jobs.[9]
  • About 1.9 million healthcare-occupation openings are projected annually in the United States from 2025 to 2035, including growth and replacement demand.[9]
  • Healthcare practitioners and technical occupations are projected to grow 7.2% in the United States from 2024 to 2034, adding 726,900 jobs.[9]
  • Pharmaceutical and medicine manufacturing employment is projected to rise from 350,500 jobs in 2024 to 369,500 in 2034, a gain of 19,000.[9]

Pay and labour costs in the healthcare and pharmaceutical industry

  • U.S. pharmacy technicians had mean annual wages of $46,620 and employment of 471,680 in May 2025.[9]
  • U.S. pharmacists had a median annual wage of $140,910 in May 2025; hospital pharmacists had a median of $157,290.[9]
  • The median annual wage for U.S. healthcare practitioners and technical occupations was $86,530 in May 2025.[9]

Skills and certification in the healthcare and pharmaceutical industry

  • In 2024, 5,110 actively practicing U.S. pharmacists provided usable responses to the National Pharmacist Workforce Study.[10]
  • 93% of U.S. MD and DO graduates matched to a first-year residency position in 2024, representing 25,877 matched graduates out of 27,788.[7]
  • U.S. healthcare occupations are projected to generate about 1.9 million annual openings from 2025 to 2035, sustaining demand for healthcare qualifications.[9]

10 Statistics

Pricing

Federal payment parameters and telehealth fees are specified for 2026, including $33.40 for the Medicare Physician Fee Schedule conversion factor.

Fees and price levels in the healthcare and pharmaceutical industry

  • $33.40 is the 2026 Medicare Physician Fee Schedule conversion factor for nonqualifying physicians and practitioners in the United States.[3]
  • $33.57 is the 2026 Medicare Physician Fee Schedule conversion factor for qualifying Advanced APM participants in the United States.[3]
  • $31.85 is the 2026 Medicare payment limit for the telehealth originating-site facility fee, equal to 80% of the lesser of the actual charge or $31.85.[3]

11 Statistics

Risk & Compliance

Regulatory timelines are explicit, including 60 calendar days as the maximum HIPAA period for notifying affected individuals after discovering a breach.

Regulation and licensing in the healthcare and pharmaceutical industry

  • 500 individuals is the HIPAA breach threshold requiring covered entities to notify the HHS Secretary without unreasonable delay and no later than 60 days.[11]
  • 90 days is FDA’s target for classifying human-drug manufacturing inspections under its current pharmaceutical compliance process.[12]
  • 60 calendar days is the maximum HIPAA period for notifying affected individuals after discovering a breach of unsecured protected health information.[11]

Client data and confidentiality in the healthcare and pharmaceutical industry

  • 74,299 small breach reports affected approximately 340,618 individuals in U.S. healthcare and related HIPAA-regulated entities during 2024.[11]
  • 1,500 small breach reports came from U.S. business associates and affected 29,221 individuals during 2024.[11]
  • 68,761 small breach reports came from U.S. healthcare providers and affected 272,139 individuals during 2024.[11]

Incidents, safety and loss events in the healthcare and pharmaceutical industry

  • 33.1 recordable cases per 100 full-time workers occurred in U.S. health care and social assistance during 2024.[9]
  • 27.1 recordable cases per 100 full-time workers occurred in U.S. hospitals during 2024.[9]
  • 2.0 recordable cases per 100 full-time workers occurred in U.S. nursing and residential care facilities during 2024.[9]

12 Statistics

Market Structure

Trade flows in health and pharmaceuticals span final and intermediate categories, including €99 billion of extra-EU intermediate exports in 2025.

Cross-border activity and trade in the healthcare and pharmaceutical industry

  • €87 billion of extra-EU final exports in 2025 were classified as health, pharmaceuticals, education, cultural and sport services, equal to 20% of final service exports.[13]
  • €99 billion of extra-EU intermediate exports in 2025 were classified as health, pharmaceuticals, education, cultural and sport services, representing 9% of the category’s exports.[13]
  • €60 billion of extra-EU final imports in 2025 were classified as health, pharmaceuticals, education, cultural and sport services, equal to 24% of final service imports.[13]
  • €124 billion of extra-EU intermediate imports in 2025 were classified as health, pharmaceuticals, education, cultural and sport services, representing 11% of the category’s imports.[13]

13 Statistics

Sustainability

Disclosure breadth is substantial, with 60% of the top 100 U.S. and Canadian pharmaceutical companies examined by SGS disclosing greenhouse-gas emissions.

Energy, emissions and disclosure in the healthcare and pharmaceutical industry

  • 60% of the top 100 U.S. and Canadian pharmaceutical companies examined by SGS disclosed greenhouse-gas emissions as an environmental topic, while 51% had improvement targets for it.[14]
  • 75% of surveyed EFPIA pharmaceutical companies had comprehensive climate targets covering Scope 1, Scope 2 and Scope 3 emissions in 2025.[15]
  • More than two-thirds of surveyed EFPIA pharmaceutical companies had committed to decreasing greenhouse-gas emissions in 2025, and 90% of those companies aligned targets with SBTi guidelines.[15]
  • 66% of the 100 largest pharmaceutical companies doing business in the United States and Canada publicly disclosed ESG or sustainability performance data.[14]

Key questions about the healthcare and pharmaceutical industry

What is the size of the U.S. healthcare market in 2025?
U.S. national health spending was projected at $5.7 trillion in 2025, equal to 18.4% of GDP.
How fast does U.S. health spending grow over the decade?
CMS projects U.S. national health expenditures to grow at an average annual rate of 5.4% from 2025 through 2034, reaching approximately $9.0 trillion by 2034.
Which companies lead the healthcare and pharmaceutical industry?
Eli Lilly and Company stands out for innovative medicines and biologics because its 2025 revenue reached $65.2 billion with Mounjaro and Zepbound, while Roche is the pick for pharmaceuticals and diagnostics since it reported CHF61.5 billion in 2025 sales.
What technology shift shows the strongest hospital adoption signal in recent data?
Predictive AI integrated with electronic health records reached 71% of U.S. non-federal acute-care hospitals in 2024, up from 66% in 2023.
How concentrated is the global prescription pharmaceutical market by geography?
The United States accounted for 53% of global prescription pharmaceutical sales by value in 2025, compared with 24% for Europe and 11% for Japan.
What is the scale of novel drug innovation in the U.S. in 2025?
The FDA Center for Drug Evaluation and Research approved 46 novel drugs in calendar 2025, with 39, or 85%, approved on the first review cycle.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 21). Healthcare And Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/healthcare-and-pharmaceutical-industry-statistics
MLA
Samuel Norberg. "Healthcare And Pharmaceutical Industry Statistics." Gitnux, 21 Nov 2026, https://gitnux.org/healthcare-and-pharmaceutical-industry-statistics.
Chicago
Samuel Norberg. 2026. "Healthcare And Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/healthcare-and-pharmaceutical-industry-statistics.